Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Sponsor
Daihong Liu
Study ID
NCT07576010
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Acute Graft-versus-host Disease

Eligibility Criteria

Sex
ALL
Age
N/A - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • steroids 、ruxolitinib — DRUG
    Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.

Study Details

This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

Key Dates

Start date
Jan 17, 2025
Status verified
May 2026
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group
    Patients with grade II acute GVHD who receive low-dose steroids plus ruxolitinib as first-line treatment

Primary Outcome Measure

Graft-Versus-Host Disease-Free, Relapse-Free Survival [ Time Frame: 1 years after treatment ]

Related Studies